Pfizer Price to Sales Ratio 2012-2026 | PFE
Historical PS ratio values for Pfizer (PFE) over the last 10 years. The current P/S ratio for Pfizer as of September 15, 2026 is .
| Pfizer P/S Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Sales per Share | Price to Sales Ratio |
| 2026-09-15 | 27.55 | 2.47 | |
| 2026-06-30 | 23.67 | $11.15 | 2.12 |
| 2026-03-31 | 27.15 | $11.08 | 2.45 |
| 2025-12-31 | 23.68 | $10.96 | 2.16 |
| 2025-09-30 | 23.81 | $11.00 | 2.16 |
| 2025-06-30 | 22.27 | $11.19 | 1.99 |
| 2025-03-31 | 22.84 | $10.95 | 2.09 |
| 2024-12-31 | 23.53 | $11.16 | 2.11 |
| 2024-09-30 | 25.27 | $10.60 | 2.38 |
| 2024-06-30 | 24.09 | $9.89 | 2.44 |
| 2024-03-31 | 23.54 | $9.83 | 2.39 |
| 2023-12-31 | 24.06 | $10.45 | 2.30 |
| 2023-09-30 | 27.35 | $12.28 | 2.23 |
| 2023-06-30 | 29.91 | $13.85 | 2.16 |
| 2023-03-31 | 32.92 | $16.43 | 2.00 |
| 2022-12-31 | 40.96 | $17.66 | 2.32 |
| 2022-09-30 | 34.68 | $17.45 | 1.99 |
| 2022-06-30 | 41.24 | $17.69 | 2.33 |
| 2022-03-31 | 40.39 | $16.16 | 2.50 |
| 2021-12-31 | 45.72 | $14.27 | 3.20 |
| 2021-09-30 | 33.01 | $12.12 | 2.72 |
| 2021-06-30 | 29.79 | $9.75 | 3.06 |
| 2021-03-31 | 27.29 | $8.17 | 3.34 |
| 2020-12-31 | 27.43 | $7.41 | 3.70 |
| 2020-09-30 | 25.68 | $5.70 | 4.50 |
| 2020-06-30 | 22.66 | $6.12 | 3.70 |
| 2020-03-31 | 22.40 | $6.70 | 3.34 |
| 2019-12-31 | 26.61 | $7.19 | 3.70 |
| 2019-09-30 | 24.17 | $7.06 | 3.42 |
| 2019-06-30 | 28.87 | $7.03 | 4.10 |
| 2019-03-31 | 28.06 | $6.96 | 4.03 |
| 2018-12-31 | 28.59 | $6.81 | 4.20 |
| 2018-09-30 | 28.64 | $8.88 | 3.23 |
| 2018-06-30 | 23.38 | $8.83 | 2.65 |
| 2018-03-31 | 22.65 | $8.71 | 2.60 |
| 2017-12-31 | 22.90 | $8.68 | 2.64 |
| 2017-09-30 | 22.37 | $8.63 | 2.59 |
| 2017-06-30 | 20.84 | $8.57 | 2.43 |
| 2017-03-31 | 21.02 | $8.57 | 2.45 |
| 2016-12-31 | 19.76 | $8.56 | 2.31 |
| 2016-09-30 | 20.40 | $8.59 | 2.37 |
| 2016-06-30 | 21.03 | $8.41 | 2.50 |
| 2016-03-31 | 17.55 | $8.17 | 2.15 |
| 2015-12-31 | 18.92 | $7.81 | 2.42 |
| 2015-09-30 | 18.26 | $7.60 | 2.40 |
| 2015-06-30 | 19.35 | $7.60 | 2.55 |
| 2015-03-31 | 19.91 | $7.68 | 2.59 |
| 2014-12-31 | 17.67 | $7.71 | 2.29 |
| 2014-09-30 | 16.63 | $7.63 | 2.18 |
| 2014-06-30 | 16.55 | $7.60 | 2.18 |
| 2014-03-31 | 17.75 | $7.44 | 2.38 |
| 2013-12-31 | 16.78 | $7.40 | 2.27 |
| 2013-09-30 | 15.62 | $7.14 | 2.19 |
| 2013-06-30 | 15.11 | $6.97 | 2.17 |
| 2013-03-31 | 15.44 | $7.00 | 2.21 |
| 2012-12-31 | 13.30 | $7.25 | 1.83 |
| 2012-09-30 | 13.06 | $6.99 | 1.87 |
| 2012-06-30 | 11.98 | $7.39 | 1.62 |
| 2012-03-31 | 11.68 | $7.62 | 1.53 |
| 2011-12-31 | 11.04 | $7.71 | 1.43 |
| 2011-09-30 | 8.93 | $8.17 | 1.09 |
| 2011-06-30 | 10.29 | $8.03 | 1.28 |
| 2011-03-31 | 10.05 | $8.08 | 1.24 |
| 2010-12-31 | 8.58 | $8.07 | 1.06 |
| 2010-09-30 | 8.32 | $8.40 | 0.99 |
| 2010-06-30 | 6.84 | $8.13 | 0.84 |
| 2010-03-31 | 8.14 | $7.63 | 1.07 |
| 2009-12-31 | 8.55 | $7.20 | 1.19 |
| 2009-09-30 | 7.70 | $6.78 | 1.14 |
| 2009-06-30 | 6.91 | $6.84 | 1.01 |
| 2009-03-31 | 6.21 | $7.01 | 0.88 |
| 2008-12-31 | 7.90 | $7.16 | 1.10 |
| 2008-09-30 | 8.08 | $7.18 | 1.13 |
| 2008-06-30 | 7.53 | $7.14 | 1.05 |
| 2008-03-31 | 8.88 | $6.93 | 1.28 |
| 2007-12-31 | 9.51 | $6.94 | 1.37 |
| 2007-09-30 | 10.10 | $6.82 | 1.48 |
| 2007-06-30 | 10.45 | $6.77 | 1.54 |
| 2007-03-31 | 10.21 | $6.80 | 1.50 |
| 2006-12-31 | 10.36 | $6.63 | 1.56 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $157.995B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1071.528B | 36.15 |
| Johnson & Johnson (JNJ) | United States | $641.804B | 24.52 |
| AbbVie (ABBV) | United States | $462.493B | 24.08 |
| Merck (MRK) | United States | $357.370B | 45.12 |
| Roche Holding AG (RHHBY) | Switzerland | $349.105B | 0.00 |
| Novartis AG (NVS) | Switzerland | $265.214B | 16.01 |
| Novo Nordisk (NVO) | Denmark | $194.004B | 10.81 |
| Sanofi (SNY) | France | $105.050B | 8.84 |
| Bayer (BAYRY) | Germany | $56.081B | 9.98 |
| Innoviva (INVA) | United States | $1.510B | 5.16 |